Pathogenics and Egenix to merge

New York, May 4 - Pathogenics, Inc. said it has agreed to merge with Egenix, Inc.

Pathogenics will be the surviving company after the transaction but it will change its name to Egenix, Inc.

Egenix's stock will be converted into Pathogenics stock on a one-for-one basis.

Meanwhile, Pathogenics will carry out a 100-for-1 reverse split. Its existing stockholders will own 6% of the merged company.

Pathogenics is a biopharmaceutical company located in Hingham, Mass.

Egenix is a privately held biotechnology company developing diagnostic and therapeutic products for cancer patients. Its corporate headquarters are in Millbrook, N.Y.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.